AGILE THERAPEUTICS INC (AGRX) Stock Price & Overview

NASDAQ:AGRXUS00847L3087

Current stock price

0.6022 USD
+0.06 (+10.11%)
At close:
0.2408 USD
-0.36 (-60.01%)
After Hours:

The current stock price of AGRX is 0.6022 USD. Today AGRX is up by 10.11%. In the past month the price decreased by -25.49%. In the past year, price decreased by -94.62%.

AGRX Key Statistics

52-Week Range0.504 - 11.5
Current AGRX stock price positioned within its 52-week range.
1-Month Range0.504 - 0.878
Current AGRX stock price positioned within its 1-month range.
Market Cap
1.512M
P/E
N/A
Fwd P/E
0.89
EPS (TTM)
-13.33
Dividend Yield
N/A

AGRX Stock Performance

Today
+10.11%
1 Week
+7.54%
1 Month
-25.49%
3 Months
-69.12%
Longer-term
6 Months -74.91%
1 Year -94.62%
2 Years -99.86%
3 Years -99.99%
5 Years -99.98%
10 Years N/A

AGRX Stock Chart

AGILE THERAPEUTICS INC / AGRX Daily stock chart

AGRX Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to AGRX. When comparing the yearly performance of all stocks, AGRX is a bad performer in the overall market: 99.5% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

AGRX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to AGRX. AGRX may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AGRX Earnings

Next Earnings DateMay 9, 2024
Last Earnings DateMar 28, 2024
PeriodQ4 / 2023
EPS Reported-$1.51
Revenue Reported
EPS Surprise -60.91%
Revenue Surprise %

AGRX Forecast & Estimates

7 analysts have analysed AGRX and the average price target is 5.1 USD. This implies a price increase of 746.89% is expected in the next year compared to the current price of 0.6022.

For the next year, analysts expect an EPS growth of 93.92% and a revenue growth 101% for AGRX


Analysts
Analysts82.86
Price Target5.1 (746.89%)
EPS Next Y93.92%
Revenue Next Year101%

AGRX Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

AGRX Financial Highlights

Over the last trailing twelve months AGRX reported a non-GAAP Earnings per Share(EPS) of -13.33. The EPS increased by 97.64% compared to the year before.


Income Statements
Revenue(TTM)19.97M
Net Income(TTM)8.24M
Industry RankSector Rank
PM (TTM) 41.26%
ROA 75.6%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%98.98%
Sales Q2Q%122%
EPS 1Y (TTM)97.64%
Revenue 1Y (TTM)137.74%

AGRX Ownership

Ownership
Inst Owners0.07%
Shares2.51M
Float0
Ins Owners105.84%
Short Float %N/A
Short RatioN/A

About AGRX

Company Profile

AGRX logo image Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. The company is headquartered in Princeton, New Jersey and currently employs 22 full-time employees. The company went IPO on 2014-05-22. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The firm commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.

Company Info

IPO: 2014-05-22

AGILE THERAPEUTICS INC

500 College Road East, Suite 310

Princeton NEW JERSEY 08540 US

CEO: Alfred Altomari

Employees: 22

AGRX Company Website

Phone: 16096831880

AGILE THERAPEUTICS INC / AGRX FAQ

Can you describe the business of AGILE THERAPEUTICS INC?

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. The company is headquartered in Princeton, New Jersey and currently employs 22 full-time employees. The company went IPO on 2014-05-22. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The firm commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.


Can you provide the latest stock price for AGILE THERAPEUTICS INC?

The current stock price of AGRX is 0.6022 USD. The price increased by 10.11% in the last trading session.


Does AGILE THERAPEUTICS INC pay dividends?

AGRX does not pay a dividend.


How is the ChartMill rating for AGILE THERAPEUTICS INC?

AGRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the sector and industry classification for AGILE THERAPEUTICS INC?

AGILE THERAPEUTICS INC (AGRX) operates in the Health Care sector and the Pharmaceuticals industry.


Is AGILE THERAPEUTICS INC (AGRX) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AGRX.


What is the next earnings date for AGRX stock?

AGILE THERAPEUTICS INC (AGRX) will report earnings on 2024-05-09, before the market open.